Literature DB >> 11353541

A robust method for the preparation and purification of antibody/streptavidin conjugates.

M D Hylarides1, R W Mallett, D L Meyer.   

Abstract

The many uses of antibody-protein conjugates, especially antibody-streptavidin conjugates, give rise to the need for a reliable conjugation method offering reasonable yields and reproducible quality. We describe a method for preparing antibody-streptavidin conjugates that has consistently produced conjugates of quality and in sufficient quantity to be used in the clinical development and evaluation of the Pretarget delivery system. In this method antibody disulfides are reduced to generate reactive thiols, and maleimides are linked to streptavidin with the heterobifunctional cross-linking agent, SMCC. The two activated proteins are then mixed briefly before the conjugation is terminated with an oxidizing agent that reforms disulfides from unreacted thiols. The preponderance of the conjugate produced is 1:1 and 1:2 Ab:SA conjugate. This fraction is isolated from unconjugated proteins and high molecular weight byproduct by iminobiotin affinity and ion-exchange chromatography. The resulting conjugate is at least 90% 1:1 + 1:2 Ab:SA conjugate, contains no SA or Ab, and is produced reproducibly in 37% yield.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353541     DOI: 10.1021/bc0001286

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

1.  Intracellular delivery system for antibody-Peptide drug conjugates.

Authors:  Geoffrey Y Berguig; Anthony J Convertine; Shani Frayo; Hanna B Kern; Erik Procko; Debashish Roy; Selvi Srinivasan; Daciana H Margineantu; Garrett Booth; Maria Corinna Palanca-Wessels; David Baker; David Hockenbery; Oliver W Press; Patrick S Stayton
Journal:  Mol Ther       Date:  2015-02-11       Impact factor: 11.454

2.  Iminobiotin binding induces large fluorescent enhancements in avidin and streptavidin fluorescent conjugates and exhibits diverging pH-dependent binding affinities.

Authors:  Marc P Raphael; Catherine A Rappole; Lynn K Kurihara; Joseph A Christodoulides; Syed N Qadri; Jeff M Byers
Journal:  J Fluoresc       Date:  2010-11-03       Impact factor: 2.217

3.  Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.

Authors:  Maria C Palanca-Wessels; Anthony J Convertine; Richelle Cutler-Strom; Garrett C Booth; Fan Lee; Geoffrey Y Berguig; Patrick S Stayton; Oliver W Press
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

4.  Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

Authors:  Anastasia Pantelias; John M Pagel; Nathan Hedin; Laura Saganic; Shani Wilbur; Donald K Hamlin; D Scott Wilbur; Yukang Lin; Diane Stone; Don Axworthy; Ajay K Gopal; Oliver W Press
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

5.  Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.

Authors:  Geoffrey Y Berguig; Anthony J Convertine; Julie Shi; Maria Corinna Palanca-Wessels; Craig L Duvall; Suzie H Pun; Oliver W Press; Patrick S Stayton
Journal:  Mol Pharm       Date:  2012-11-05       Impact factor: 4.939

6.  Monovalent streptavidin that senses oligonucleotides.

Authors:  Steven K Taylor; Jingxian Wang; Natasa Kostic; Milan N Stojanovic
Journal:  Angew Chem Int Ed Engl       Date:  2013-04-19       Impact factor: 15.336

7.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

Authors:  D Scott Wilbur; Monica S Thakar; Donald K Hamlin; Erlinda B Santos; Ming-Kuan Chyan; Hirohisa Nakamae; John M Pagel; Oliver W Press; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2009-09-04       Impact factor: 4.774

8.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.

Authors:  John M Pagel; Nural Orgun; Donald K Hamlin; D Scott Wilbur; Theodore A Gooley; Ajay K Gopal; Steven I Park; Damian J Green; Yukang Lin; Oliver W Press
Journal:  Blood       Date:  2009-01-05       Impact factor: 22.113

9.  Amine Landscaping to Maximize Protein-Dye Fluorescence and Ultrastable Protein-Ligand Interaction.

Authors:  Michael T Jacobsen; Michael Fairhead; Per Fogelstrand; Mark Howarth
Journal:  Cell Chem Biol       Date:  2017-07-27       Impact factor: 8.116

10.  Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.

Authors:  Maria C Palanca-Wessels; Garrett C Booth; Anthony J Convertine; Brittany B Lundy; Geoffrey Y Berguig; Michael F Press; Patrick S Stayton; Oliver W Press
Journal:  Oncotarget       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.